The use of borneol as an enhancer for targeting aprotinin-conjugated PEG-PLGA nanoparticles to the brain

Pharmaceutical Research

Volumn 30, Issue 10, 2013, Pages 2560-2572

  Zhang, Lin ^a,b,c   Han, Limei ^a,b   Qin, Jing ^a,b   Lu, Weiyue ^a,b   Wang, Jianxin ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c SHAOXING PEOPLE S HOSPITAL   (China)

Author keywords

aprotinin; borneol; brain targeting; huperzine A; nanoparticles

Indexed keywords

APROTININ CONJUGATED POLY(ETHYLENE GLYCOL) POLY(LEVO LACTIC CO GLYCOLIC ACID) NANOPARTICLE; BORNEOL; HUPERZINE A; NANOPARTICLE; PENETRATION ENHANCING AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CAPILLARY ENDOTHELIAL CELL; CELL TRANSPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RETENTION; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; MAZE TEST; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

ALKALOIDS; ALZHEIMER DISEASE; ANIMALS; APROTININ; BEHAVIOR, ANIMAL; BORNANES; BRAIN; ENDOTHELIAL CELLS; MALE; MAZE LEARNING; MICE; MICE, NUDE; NANOCONJUGATES; NEUROPROTECTIVE AGENTS; POLYESTERS; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES; TISSUE DISTRIBUTION;

EID: 84883872595     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1055-y     Document Type: Article

References (40)

1. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13-25.
2. Popescu BO, Toescu EC, Popescu LM, Bajenaru O, Muresanu DF, Schultzberg M, et al. Blood-brain barrier alterations in ageing and dementia. J Neurol Sci. 2009;283:99-106.
3. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release. 2009;134:55-61.
4. Huang R, Ke W, Han L, Liu Y, Shao K, Jiang C, et al. Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res Bull. 2010;81:600-4.
5. Lin LN, Liu Q, Song L, Liu FF, Sha JX. Recent advances in nanotechnology based drug delivery to the brain. Cytotechnology. 2010;62:377-80.
6. Craparo EF, Bondi ML, Pitarresi G, Cavallaro G. Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci Ther. 2011;17:670-7.
7. Beduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials. 2007;28:4947-67.
8. Jonesand AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res. 2007;24:1759-71.
9. Demeule M, Currie J-C, Bertrand Y, Ché C, Nguyen T, Régina A, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. J Neurochem. 2008;106:1534-44.
10. Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-β peptide in a blood-brain barrier in vitro model. Neurobiol Dis. 2008;30:94-102.
11. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909-18.
12. Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther. 2008;324:1064-72.
13. Demeule M, Currie JC, Bertrand Y, Che C, Nguyen T, Regina A, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem. 2008;106:1534-44.
14. Bhatia S, Letizia C, Api A. Fragrance material review on borneol. Food Chem Toxicol. 2008;46:S77-80.
15. Chai G, Pan Y, Li F. Effect of borneol/mentholum eutectic mixture on nasal-brain delivery of neurotoxin loaded nanoparticles. Zhongguo Zhong Yao Za Zhi. 2009;34:698-701.
16. Lu Y, Du SY, Chen XL, Wu Q, Song X, Xu B, et al. Enhancing effect of natural borneol on the absorption of geniposide in rat via intranasal administration. J Zhejiang Univ Sci B. 2011;12:143-8.
17. Cai Z, Hou S, Li Y, Zhao B, Yang Z, Xu S, et al. Effect of borneol on the distribution of gastrodin to the brain in mice via oral administration. J Drug Target. 2008;16:178-84.
18. Gao CY, Li XR, Li YH, Wang LJ, Xue M. Pharmacokinetic interaction between puerarin and edaravone, and effect of borneol on the brain distribution kinetics of puerarin in rats. J Pharm Pharmacol. 2010;62:360-7.
19. Yanyu X, Qineng P, Zhipeng C. The enhancing effect of synthetical borneol on the absorption of tetramethylpyrazine phosphate in mouse. Int J Pharm. 2007;337:74-9.
20. Xiao XQ, Zhang HY, Tang XC. Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res. 2002;67:30-6.
21. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006;27:1-26.
22. Wang B-s, Wang H, Wei Z-h, Song Y-y, Zhang L, Chen H-z. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. J Neural Transm. 2009;116:457-65.
23. Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release. 2010;143:136-42.
24. Ye JC, Zeng S, Zheng GL, Chen GS. Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs. Int J Pharm. 2008;356:187-92.
25. Wen Z, Yan Z, Hu K, Pang Z, Cheng X, Guo L, et al. Odorranalectin- conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J Control Release. 2011;151:131-8.
26. Chu D, Fu X, Liu W, Liu K, Li Y. Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm. 2006;325:116-23.
27. Mutlu O, Ulak G, Celikyurt IK, Akar FY, Erden F. Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice. Pharmacol Biochem Behav. 2011;98:398-404.
28. Ren J, Zou M, Gao P, Wang Y, Cheng G. Tissue distribution of borneol-modified ganciclovir-loaded solid lipid nanoparticles in mice after intravenous administration. Eur J Pharm Biopharm. 2013;83:141-148.
29. Wu CJ, Huang QW, Qi HY, Guo P, Hou SX. Promoting effect of borneol on the permeability of puerarin eye drops and timolol maleate eye drops through the cornea in vitro. Pharmazie. 2006;61:783-8.
30. Frozza RL, Horn AP, Hoppe JB, da Silva T, Simão F, Gerhardt D, et al. Aβ1-42 and Aβ25-35 peptides induce similar toxicity in organotypic hippocampal slice cultures and this effect can be prevented by resveratrol. Alzheimers Dement. 2009;5:P175.
31. Galoyan AA, Sarkissian JS, Chavushyan VA, Meliksetyan IB, Avagyan ZE, Poghosyan MV, et al. Neuroprotection by hypothalamic peptide proline-rich peptide-1 in Abeta25-35 model of Alzheimer's disease. Alzheimers Dement J Alzheimers Assoc. 2008;4:332-44.
32. Zhou Y, Li W, Chen L, Ma S, Ping L, Yang Z. Enhancement of intestinal absorption of akebia saponin D by borneol and probenecid in situ and in vitro. Environ Toxicol Pharmacol. 2010;29:229-34.
33. Chenand YM, Wang NS. Effect of borneol on the intercellular tight junction and pinocytosis vesicles in vitro blood-brain barrier model. Chin J Integr Tradit West Med. 2004;24:632-4.
34. He H, Shen Q, Li J. Effects of borneol on the intestinal transport and absorption of two P-glycoprotein substrates in rats. Arch Pharm Res. 2011;34:1161-70.
35. Chenand YM, Wang NS. Effect of borneol on the intercellular tight junction and pinocytosis vesicles in vitro blood-brain barrier model. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004;24:632-4.
36. Li WR, Yao LM, Mi SQ, Wang NS. Relation of openness of blood-brain barrier with histamine and 5-hydroxy-tryptamine. Chin J Clin Rehabil. 2006;10:167-169.
37. Wei C, Wu G. Research advance in pharmacological effect of borneol and the underlying mechanism. Int J Pathol Clin Med. 2010;5:021.
38. Wu S, Cheng G, Feng Y. Progress in studies on pharmacology of borneol. Chin Tradit Herb Drugs. 2001;32:1143-4.
39. Wangand NS, Liang MR. Stuty of the effect of borneol on improving the activity of herbs. J Tradit Chin Med. 1994;35:46-7.
40. Zhao B, Liu Q. Comparison between borneol-induced opening of blood-brain barrier and its pathological opening. Tradit Chin Drug Res Clin Pharmacol. 2002;5:007.